The Potential for Repurposing Anti-TNF As a Therapy for the Treatment of COVID-19

Overview

Journal Med

Publisher Cell Press

Specialty General Medicine

Date 2020 Dec 9

PMID 33294881

Citations 75

Authors

Philip C Robinson

David F L Liew

Jean W Liew

Claudia Monaco

Duncan Richards

Senthuran Shivakumar

Helen L Tanner

Marc Feldmann

Affiliations

Soon will be listed here.

Abstract

Coronavirus disease 2019 (COVID-19) currently has few effective treatments. Given the uncertainty surrounding the effectiveness and uptake of a vaccine, it is important that the search for treatments continue. An exaggerated inflammatory state is likely responsible for much of the morbidity and mortality in COVID-19. Elevated levels of tumor necrosis factor (TNF), a key pro-inflammatory cytokine, have been shown to be associated with increased COVID-19 mortality. In patients with rheumatoid arthritis, TNF blockade reduces not only biologically active TNF but other pro-inflammatory cytokines important in COVID-19 hyperinflammation. Observational data from patients already on anti-TNF therapy show a reduced rate of COVID-19 poor outcomes and death compared with other immune-suppressing therapies. Anti-TNF has a long history of safe use, including in special at-risk populations, and is widely available. The case to adequately assess anti-TNF as a treatment for COVID-19 is compelling.

Citing Articles

The Impact of Infliximab on Hyperinflammation State in Hospitalized COVID-19 Patients: A Retrospective Study.

Saied Y, Abou Warda A, Allam R, Syed W, Al-Rawi M, Iqbal A Medicina (Kaunas). 2024; 60(10).

PMID: 39459457 PMC: 11509666. DOI: 10.3390/medicina60101670.

Association between COVID-19 infection and uveitis flare in patients with Behcet's disease, a retrospective multicenter cohort study.

Song H, Zhang Y, Chen Y, Zhang M, Gao F, Zhao C Graefes Arch Clin Exp Ophthalmol. 2024; 263(1):209-215.

PMID: 39141118 DOI: 10.1007/s00417-024-06536-4.

Factors Associated with Mortality in Patients with Coronavirus Disease (COVID-19) in Babol, North of Iran.

Babaei M, Heidari B, Ghorbani H, Ahmadnia Z, Rouhi S, Sadeghi Haddad Zavareh M Infect Disord Drug Targets. 2024; 24(6):e090224226818.

PMID: 38343046 DOI: 10.2174/0118715265209731240129042916.

Unveiling COVID-19 Secrets: Harnessing Cytokines as Powerful Biomarkers for Diagnosis and Predicting Severity.

Wolszczak-Biedrzycka B, Dorf J, Wojewodzka-Zelezniakowicz M, Zendzian-Piotrowska M, Dymicka-Piekarska V, Matowicka-Karna J J Inflamm Res. 2023; 16:6055-6070.

PMID: 38107380 PMC: 10723593. DOI: 10.2147/JIR.S439217.

A Comparison of the Adverse Effects and Utility of Different Monoclonal Antibodies for SARS-CoV-2: A Retrospective Cohort Study.

Knopp B, Weiss H, Fahmy S, Goldstein E, Parmar J Cureus. 2023; 15(8):e43094.

PMID: 37680398 PMC: 10482545. DOI: 10.7759/cureus.43094.

References

Sudo M, Iida K, Tsutsui H, Mitani K, Jimbo M, Hatano E . Blockade of Tumor Necrosis Factor by Etanercept Prevents Postoperative Adhesion Formation in Mice. Cell Physiol Biochem. 2020; 54(5):1041-1053. DOI: 10.33594/000000286. View

Salvarani C, Dolci G, Massari M, Merlo D, Cavuto S, Savoldi L . Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2020; 181(1):24-31. PMC: 7577199. DOI: 10.1001/jamainternmed.2020.6615. View

Nurmohamed M, Bao Y, Signorovitch J, Trahey A, Mulani P, Furst D . Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis. RMD Open. 2015; 1(1):e000080. PMC: 4612693. DOI: 10.1136/rmdopen-2015-000080. View

Abraham E, Wunderink R, Silverman H, Perl T, Nasraway S, Levy H . Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA. 1995; 273(12):934-41. View

Sumida K, Molnar M, Potukuchi P, Hassan F, Thomas F, Yamagata K . Treatment of rheumatoid arthritis with biologic agents lowers the risk of incident chronic kidney disease. Kidney Int. 2018; 93(5):1207-1216. PMC: 5911428. DOI: 10.1016/j.kint.2017.11.025. View

Su Y, Chen D, Yuan D, Lausted C, Choi J, Dai C . Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19. Cell. 2020; 183(6):1479-1495.e20. PMC: 7598382. DOI: 10.1016/j.cell.2020.10.037. View

Winthrop K, Brunton A, Beekmann S, Polgreen P, Baddley J, Saag K . SARS CoV-2 infection among patients using immunomodulatory therapies. Ann Rheum Dis. 2020; 80(2):269-271. DOI: 10.1136/annrheumdis-2020-218580. View

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130(5):2620-2629. PMC: 7190990. DOI: 10.1172/JCI137244. View

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

10.

Bradley B, Maioli H, Johnston R, Chaudhry I, Fink S, Xu H . Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series. Lancet. 2020; 396(10247):320-332. PMC: 7365650. DOI: 10.1016/S0140-6736(20)31305-2. View

11.

Feldmann M, Maini R . Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med. 2003; 9(10):1245-50. DOI: 10.1038/nm939. View

12.

Amigues I, Pearlman A, Patel A, Reid P, Robinson P, Sinha R . Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation. Expert Rev Clin Immunol. 2020; 16(12):1185-1204. PMC: 7879704. DOI: 10.1080/1744666X.2021.1847084. View

13.

Mezouar S, Diarra I, Roudier J, Desnues B, Mege J . Tumor Necrosis Factor-Alpha Antagonist Interferes With the Formation of Granulomatous Multinucleated Giant Cells: New Insights Into Infection. Front Immunol. 2019; 10:1947. PMC: 6702871. DOI: 10.3389/fimmu.2019.01947. View

14.

Middleton E, He X, Denorme F, Campbell R, Ng D, Salvatore S . Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood. 2020; 136(10):1169-1179. PMC: 7472714. DOI: 10.1182/blood.2020007008. View

15.

Channappanavar R, Fehr A, Vijay R, Mack M, Zhao J, Meyerholz D . Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe. 2016; 19(2):181-93. PMC: 4752723. DOI: 10.1016/j.chom.2016.01.007. View

16.

Mariette X, Forger F, Abraham B, Flynn A, Molto A, Flipo R . Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2017; 77(2):228-233. PMC: 5867410. DOI: 10.1136/annrheumdis-2017-212196. View

17.

Mann E, Menon M, Knight S, Konkel J, Jagger C, Shaw T . Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19. Sci Immunol. 2020; 5(51). PMC: 7857390. DOI: 10.1126/sciimmunol.abd6197. View

18.

Feldmann M, Maini R, Woody J, Holgate S, Winter G, Rowland M . Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020; 395(10234):1407-1409. PMC: 7158940. DOI: 10.1016/S0140-6736(20)30858-8. View

19.

Chen L, Long X, Xu Q, Tan J, Wang G, Cao Y . Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients. Cell Mol Immunol. 2020; 17(9):992-994. PMC: 7332851. DOI: 10.1038/s41423-020-0492-x. View

20.

Aid M, Busman-Sahay K, Vidal S, Maliga Z, Bondoc S, Starke C . Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques. Cell. 2020; 183(5):1354-1366.e13. PMC: 7546181. DOI: 10.1016/j.cell.2020.10.005. View